

Pharmaceutical Benefits Advisory Committee

Email: PBAC@health.gov.au

Address all mail to:
PBAC Secretariat
GPO Box 9848
Canberra ACT 2601

DELISTING OF PHARMACEUTICAL BENEFIT ITEMS EFFECTIVE 01 JANUARY 2025

Following is the advice of the Pharmaceutical Benefits Advisory Committee (PBAC) concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act 1953*, with effect from the above date.

Item

PBAC Advice

Hypromellose with carbomer 980

The sponsor requested the delisting of Genteal[®] gel (hypromellose with carbomer 980) and HPMC PAA (hypromellose with carbomer 980) from the Pharmaceutical Benefits Scheme (PBS).

The PBAC noted there are multiple alternative lubricating eye gel products available. The PBAC advised the delisting of these products would not result in an unmet clinical need.

Brendon Wheatley
Director (A/g), PBAC Governance
Office of Health Technology Assessment
Technology Assessment and Access Division
06 December 2024